Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) Insider Jo Ann Beltramello Sells 13,356 Shares

Share on StockTwits

Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) insider Jo Ann Beltramello sold 13,356 shares of Momenta Pharmaceuticals stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $30.03, for a total value of $401,080.68. Following the transaction, the insider now owns 70,522 shares in the company, valued at approximately $2,117,775.66. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Jo Ann Beltramello also recently made the following trade(s):

  • On Friday, February 7th, Jo Ann Beltramello sold 2,691 shares of Momenta Pharmaceuticals stock. The shares were sold at an average price of $31.06, for a total transaction of $83,582.46.
  • On Friday, January 24th, Jo Ann Beltramello sold 1,219 shares of Momenta Pharmaceuticals stock. The shares were sold at an average price of $28.19, for a total transaction of $34,363.61.
  • On Tuesday, January 14th, Jo Ann Beltramello sold 122,589 shares of Momenta Pharmaceuticals stock. The shares were sold at an average price of $23.42, for a total transaction of $2,871,034.38.

NASDAQ MNTA opened at $31.88 on Friday. The company has a market cap of $3.16 billion, a P/E ratio of -14.69 and a beta of 2.01. The stock has a 50-day moving average of $26.17 and a two-hundred day moving average of $17.38. Momenta Pharmaceuticals, Inc. has a 1-year low of $9.51 and a 1-year high of $32.37.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in MNTA. Meeder Asset Management Inc. lifted its stake in Momenta Pharmaceuticals by 362.0% during the fourth quarter. Meeder Asset Management Inc. now owns 2,421 shares of the biotechnology company’s stock worth $48,000 after purchasing an additional 1,897 shares during the last quarter. Smith Asset Management Group LP purchased a new stake in Momenta Pharmaceuticals in the fourth quarter valued at approximately $62,000. Nisa Investment Advisors LLC lifted its stake in Momenta Pharmaceuticals by 611.9% in the fourth quarter. Nisa Investment Advisors LLC now owns 4,770 shares of the biotechnology company’s stock valued at $94,000 after buying an additional 4,100 shares during the last quarter. Teza Capital Management LLC purchased a new stake in Momenta Pharmaceuticals in the fourth quarter valued at approximately $228,000. Finally, Victory Capital Management Inc. lifted its stake in Momenta Pharmaceuticals by 22.0% in the fourth quarter. Victory Capital Management Inc. now owns 14,083 shares of the biotechnology company’s stock valued at $409,000 after buying an additional 2,541 shares during the last quarter. 97.03% of the stock is owned by institutional investors.

Several analysts recently issued reports on the stock. Wells Fargo & Co assumed coverage on shares of Momenta Pharmaceuticals in a report on Wednesday, November 6th. They issued an “outperform” rating on the stock. JPMorgan Chase & Co. upgraded shares of Momenta Pharmaceuticals from a “neutral” rating to an “overweight” rating and boosted their price objective for the company from $14.00 to $30.00 in a report on Tuesday, January 14th. BidaskClub upgraded shares of Momenta Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Wednesday, December 11th. SunTrust Banks boosted their price objective on shares of Momenta Pharmaceuticals to and gave the company a “buy” rating in a report on Wednesday, January 15th. Finally, ValuEngine lowered shares of Momenta Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, December 24th. Four investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. The company has an average rating of “Buy” and an average target price of $31.79.

Momenta Pharmaceuticals Company Profile

Momenta Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases in the United States. Its novel therapeutic programs include M281, a fully-human anti-neonatal Fc receptor (FcRn), aglycosylated immunoglobulin G (IgG1), and monoclonal antibody to reduce circulating IgG antibodies by blocking endogenous IgG recycling via FcRn; M230, a recombinant trivalent human IgG1 Fc multimer containing three IgG Fc regions joined to maximize activity; and M254, a hyper-sialylated immunoglobulin to treat various inflammatory diseases, including idiopathic thrombocytopenic purpura and chronic inflammatory demyelinating polyneuropathy.

Recommended Story: Most Volatile Stocks – What Investors Need to Know to Maximize ROI

Insider Buying and Selling by Quarter for Momenta Pharmaceuticals (NASDAQ:MNTA)

Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2020 BBNS.